Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
16.8M
-
Number of holders
-
15
-
Total 13F shares, excl. options
-
286K
-
Shares change
-
+286K
-
Total reported value, excl. options
-
$2.71M
-
Value change
-
+$2.71M
-
Number of buys
-
15
-
Price
-
$9.50
Significant Holders of Elicio Therapeutics, Inc. - Common Stock, par value $0.01 per share (ELTX) as of Q2 2023
15 filings reported holding ELTX - Elicio Therapeutics, Inc. - Common Stock, par value $0.01 per share as of Q2 2023.
Elicio Therapeutics, Inc. - Common Stock, par value $0.01 per share (ELTX) has 15 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 286K shares
of 16.8M outstanding shares and own 1.7% of the company stock.
Largest 10 shareholders include Nantahala Capital Management, LLC (94.9K shares), VANGUARD GROUP INC (70.8K shares), CM Management, LLC (65K shares), GEODE CAPITAL MANAGEMENT, LLC (24.2K shares), MEYER HANDELMAN CO (13.2K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (12.5K shares), BANK OF AMERICA CORP /DE/ (1.59K shares), Steward Partners Investment Advisory, LLC (1.55K shares), UBS Group AG (645 shares), and CITIGROUP INC (374 shares).
This table shows the top 15 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.